HomeCompareMAHN vs MRK

MAHN vs MRK: Dividend Comparison 2026

MAHN yields 1818.18% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAHN wins by $4103414683.78M in total portfolio value
10 years
MAHN
MAHN
● Live price
1818.18%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4103414683.84M
Annual income
$3,702,796,788,756,407.00
Full MAHN calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — MAHN vs MRK

📍 MAHN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMAHNMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MAHN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MAHN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MAHN
Annual income on $10K today (after 15% tax)
$154,545.45/yr
After 10yr DRIP, annual income (after tax)
$3,147,377,270,442,946.00/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MAHN beats the other by $3,147,377,270,434,349.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MAHN + MRK for your $10,000?

MAHN: 50%MRK: 50%
100% MRK50/50100% MAHN
Portfolio after 10yr
$2051707341.95M
Annual income
$1,851,398,394,383,260.50/yr
Blended yield
90.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MAHN
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MAHN buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMAHNMRK
Forward yield1818.18%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4103414683.84M$57.7K
Annual income after 10y$3,702,796,788,756,407.00$10,113.78
Total dividends collected$4074760433.31M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MAHN vs MRK ($10,000, DRIP)

YearMAHN PortfolioMAHN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$192,518$181,818.18$11,213$373.04+$181.3KMAHN
2$3,477,331$3,271,336.99$12,667$512.06+$3.46MMAHN
3$58,943,217$55,222,471.89$14,439$708.14+$58.93MMAHN
4$937,891,469$874,822,227.57$16,640$988.16+$937.87MMAHN
5$14,012,869,532$13,009,325,660.38$19,432$1,394.07+$14012.85MMAHN
6$196,647,994,247$181,654,223,846.76$23,057$1,992.90+$196647.97MMAHN
7$2,592,865,386,485$2,382,452,032,641.56$27,889$2,894.79+$2592865.36MMAHN
8$32,132,661,421,271$29,358,295,457,731.54$34,518$4,286.29+$32132661.39MMAHN
9$374,409,247,740,494$340,027,300,019,734.44$43,912$6,494.35+$374409247.70MMAHN
10$4,103,414,683,838,736$3,702,796,788,756,407.00$57,714$10,113.78+$4103414683.78MMAHN

MAHN vs MRK: Complete Analysis 2026

MAHNStock

Mid-Atlantic Home Health Network, Inc. provides integrated home health products and services for the home health care industry in Virginia, Maryland, and the District of Columbia. It also provides healthcare staffing and private duty nursing services to hospitals, nursing homes, and other facilities, such as clinics, correctional facilities, and schools. Mid-Atlantic was incorporated as U-Can Resources, Inc. in 1979. The company changed its name to Petro-Sers Corporation in 1993 and to Mid-Atlantic Home Health Network, Inc. in 1994. The company is based in Manassas, Virginia. Mid-Atlantic Home Health Network, Inc. is 80% owned by Oak Springs NursingHome Limited Liability Company.

Full MAHN Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MAHN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MAHN vs SCHDMAHN vs JEPIMAHN vs OMAHN vs KOMAHN vs MAINMAHN vs JNJMAHN vs ABBVMAHN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.